Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 33
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigon-Hernandez, Lorena
  • Vázquez-Morón, Sonia
  • Berenguer, Juan
  • González-García, Juan
  • Jimenez-Sousa, Maria Angeles
  • Guardiola, Josep M
  • Crespo, Manuel
  • de Los Santos, Ignacio
  • Von Wichmann, Miguel A
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador
  • Martinez, Isidoro
  • GESIDA 3603b Cohort Study Group
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Repisalud
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.

  • Brochado-Kith, Oscar
  • Martinez, Isidoro
  • Berenguer, Juan
  • Medrano, Luz Maria
  • González-García, Juan
  • Jimenez-Sousa, Maria Angeles
  • Carrero, Ana
  • Hontañón, Víctor
  • Navarro, Jordi
  • Guardiola, Josep M
  • Fernandez-Rodriguez, Amanda
  • Resino, Salvador
To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study

  • Martín-Escolano, Rubén
  • Virseda-Berdices, Ana
  • Berenguer, Juan
  • González-García, Juan
  • Brochado-Kith, Oscar
  • Fernandez-Rodriguez, Amanda
  • Díez, Cristina
  • Hontañón, Víctor
  • Marathon Study Group
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Background: Understanding the predictors of metabolic disorders in persons with HIV/HCV coinfection post-HCV therapy is crucial for improving patient outcomes. Since immune checkpoint proteins are usually upregulated in these persons with HIV/HCV coinfection, we aimed to evaluate the association between plasma immune checkpoint proteins at baseline (before HCV therapy) and metabolic disturbances during the follow-up (about 5 years after successful HCV treatment) in persons with HIV/HCV coinfection. Methods: We performed a retrospective study on 80 persons with HIV/HCV coinfection with advanced fibrosis or cirrhosis who cleared HCV infection after successful HCV therapy and were followed for about 5 years after completion of HCV treatment. Plasma samples were collected at baseline. Immune checkpoint proteins were analyzed using a Luminex 200™ analyzer. Outcomes were the development of a metabolic event (type 2 diabetes mellitus and/or dyslipidemia) and the change in Triglycerides and glucose (TyG) index. Results: During follow-up, 21 (26%) patients developed metabolic events (type 2 diabetes mellitus/dyslipidemia), and 29 (46.0%) patients had an increase in TyG during the follow-up. Low baseline values of BTLA and LAG-3, two immune checkpoint proteins, were associated with the development of metabolic events (aAMR = 0.69 and aAMR = 0.71, respectively) and with increases in TyG values (aAMR = 0.72 and aAMR = 0.70, respectively). In addition, other immune checkpoint proteins were also inversely associated with increases in TyG. Conclusion: We discovered that low plasma levels of BTLA and LAG-3 before HCV therapy significantly correlate with an increased risk of developing metabolic disorders after treatment.
Repisalud
Publicación Artículo científico (JournalArticle)

Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study

  • Martín-Escolano, Rubén
  • Virseda-Berdices, Ana
  • Berenguer, Juan
  • Resino, Salvador
  • González-García, Juan
  • Brochado-Kith, Oscar
  • Fernandez-Rodriguez, Amanda
  • Díez, Cristina
  • Hontañón, Víctor
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Various immune checkpoint proteins have been linked to cirrhosis. This study aimed to explore the association between plasma levels of these proteins measured one year after successful HCV treatment and persistently liver stiffness (defined as liver stiffness measurement (LSM) ≥ 12.5 kPa) five years after HCV treatment in people with HIV (PWH). We conducted a retrospective study involving 39 patients with HIV/HCV-coinfection who had advanced fibrosis or cirrhosis and achieved sustained virologic response (SVR). Plasma samples were obtained one year after treatment, and levels of immune checkpoints along with inflammatory biomarkers were evaluated using a Luminex 200 analyzer. Statistical analyses were performed using Generalized Linear Models (GLMs) with a gamma distribution. Spearman correlation tests were used to analyze the correlation between significant immune checkpoints and inflammatory biomarkers. Although LSM values showed a decreasing trend over the years following successful HCV treatment, this trend was not statistically significant due to substantial variability among PWH. Persistently high liver stiffness was observed in 61.5% of patients five years after HCV treatment. Elevated plasma levels of soluble BTLA, PD-1, and TIM-3 one year after HCV treatment were associated with persistently liver stiffness five years later. These significant immune checkpoints were found to correlate with inflammatory biomarkers in PWH with persistently high liver stiffness. In conclusion, increased plasma concentrations of immune checkpoints one year after successful HCV therapy were linked to persistently high liver stiffness five years later, particularly BTLA, PD-1, and TIM-3. This suggests a potential immunopathological mechanism in ongoing liver stiffness post-HCV eradication.
Repisalud
Publicación Artículo científico (JournalArticle)

Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy

  • Virseda-Berdices, Ana
  • Martín-Escolano, Rubén
  • Berenguer, Juan
  • González-García, Juan
  • Brochado-Kith, Oscar
  • Rojo, David
  • Fernandez-Rodriguez, Amanda
  • Pérez-Latorre, Leire
  • Hontañón, Víctor
  • Barbas, Coral
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Background: Combination antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) infection in people with HIV (PWH). However, a chronic state of immune activation and inflammation is maintained despite achieving HIV suppression and satisfactory immunological recovery. We aimed to determine whether the plasma metabolomic profile of PWH on long-term suppressive ART and immunologically recovered approximates the normality by comparison with healthy controls with similar age and gender. Methods: We carried out a cross-sectional study in 17 PWH on long-term ART (HIV-RNA <50 copies/mL, CD4+ ≥500 cells/mm3, and CD4+/CD8+ ≥1) and 19 healthy controls with similar age and gender. Metabolomics analysis was performed by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). The statistical association analysis was performed by principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and Generalized Linear Models (GLM) with a gamma distribution (log-link). Significance levels (p-value) were corrected for multiple testing (q-value). Results: PCA and PLS-DA analyses found no relevant differences between groups. Adjusted GLM showed 14 significant features (q-value<0.20), of which only three could be identified: lysophosphatidylcholine (LysoPC) (22:6) (q-value=0.148), lysophosphatidylethanolamine (LysoPE) (22:6) (q-value=0.050) and hydroperoxy-octadecatrienoic acid (HpOTrE)/dihydroperoxy-octadecatrienoic acid (DiHOTrE)/epoxy-octadecadienoic acid (EpODE) (q-value=0.136). These significant identified metabolites were directly correlated to plasma inflammatory biomarkers in PWH and negatively correlated in healthy controls. Conclusion: PWH on long-term ART have a metabolomic profile that is almost normal compared to healthy controls. Nevertheless, residual metabolic alterations linked to inflammatory biomarkers persist, which could favor the development of age-related comorbidities among this population.
Repisalud
Publicación Artículo científico (JournalArticle)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study

  • Medrano, Luz Maria
  • Berenguer, Juan
  • Salgüero Fernandez, Sergio
  • González-García, Juan
  • Díez, Cristina
  • Hontañón, Víctor
  • Garcia-Broncano, Pilar
  • Ibañez-Samaniego, Luis
  • Bellón, José María
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
Background: Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in HIV-infected patients with advanced HCV-related cirrhosis. Methods: We performed an observational study of 50 patients with advanced cirrhosis who received DAAs therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Epidemiological and clinical data were collected through an online form. Liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), and Child-Pugh-Turcotte (CTP) were evaluated by physicians. Plasma biomarkers were measured by multiplex immunoassay. Results: We found significant decreases in severity scores of liver disease [LSM (q-value < 0.001), HVPG (q-value = 0.011), and CTP (q-value = 0.045)] and plasma biomarkers [LBP (q-value < 0.001), IP-10 (q-value < 0.001), IL-8 (q-value < 0.001), IL-18 (q-value < 0.001), IL-1RA (q-value = 0.013), OPG (q-value < 0.001), sVCAM-1 (q-value < 0.001), sICAM-1 (q-value < 0.001), PAI-1 (q-value = 0.001), and VEGF-A (q-value = 0.006)]. We also found a significant direct association between the change in LSM values and the change in values of LBP (q-value < 0.001), IP-10 (q-value < 0.001), MCP-1 (q-value = 0.008), IL-8 (q-value < 0.001), IL-18 (q-value < 0.001), OPG (q-value = 0.004), sVCAM-1 (q-value < 0.001), sICAM-1 (q-value < 0.001), and PAI-1 (q-value = 0.002). For CTP values, we found significant positive associations with IP-10 (q-value = 0.010), IL-6 (q-value = 0.010), IL-1RA (q-value = 0.033), and sICAM-1 (q-value = 0.010). Conclusion: The HCV eradication with all-oral DAAs in HIV/HCV-coinfected patients with advanced cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis). The decrease in plasma biomarkers was mainly related to the reduction in LSM values.
Repisalud
Publicación Artículo científico (JournalArticle)

HIV status defines distinct immunological drivers of persistent portal hypertension after HCV cure in people with advanced cirrhosis.

  • Martín-Escolano, Rubén
  • Fernandez-Rodriguez, Amanda
  • Tarancon-Diez, Laura
  • Berenguer, Juan
  • Codina Márquez, Helena
  • Amigot-Sánchez, Rafael
  • González-García, Juan
  • Hontañón, Víctor
  • Pérez-Latorre, Leire
  • Ibañez-Samaniego, Luis
  • Llop-Herrera, Elba
  • Olveira, Antonio
  • Díaz, Laura
  • Martinez, Isidoro
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
Introduction: The immunological drivers of portal hypertension regression after hepatitis C virus (HCV) cure are poorly understood, particularly in the context of human immunodeficiency virus (HIV) coinfection We aimed to identify baseline immune signatures predicting the evolution of the hepatic venous pressure gradient (HVPG) in people with and without HIV (PWH/PWoH). Methods: We prospectively followed 41 individuals with advanced cirrhosis (18 PWoH, 23 PWH) who were cured of HCV with direct-acting antivirals (DAA). Baseline plasma and cellular immune markers were extensively profiled using multiplex assays and flow cytometry. We used mixed-effects modeling to test for associations between these baseline immune features and the change in HVPG over a 48-week follow-up period, with q-values controlling for false discoveries. Results: Two distinct immunological profiles of impaired HVPG regression emerged. In PWoH, impaired regression was linked to a broad proinflammatory profile [TNF-α (AMR = 1.13; q=0.012), IL17A (AMR = 1.28; q=0.012), and IL10 (AMR = 1.2; q=0.028)], a widespread total CD4+ T-cell activation [HLA-DR+ (AMR = 1.44; q<0.001) and CD38+HLA-DR+ (AMR = 1.3; q=0.007)], and robust activation across central memory (CM) and effector memory (EM) subsets. Conversely, in PWH, impaired HVPG regression was associated with sVCAM-1 (AMR = 1.58; q=0.096), and a more focused activation within EM (HLA-DR+, AMR = 1.08; q=0.030) and TemRA (CD38+HLA-DR+, AMR = 1.12; q=0.030) CD4+ T-cells. Discussion: HIV coinfection fundamentally reshapes the immunological landscape of post-cure portal hypertension recovery. The shift from systemic inflammation in PWoH to endothelial dysfunction and T-cell exhaustion in PWH reveals distinct pathological pathways. Understanding these signatures is a crucial step toward developing targeted therapies to promote complete hepatic recovery.
Repisalud
Publicación Artículo científico (JournalArticle)

Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

  • Salgüero Fernandez, Sergio
  • Rojo, David
  • Berenguer, Juan
  • González-García, Juan
  • Fernandez-Rodriguez, Amanda
  • Brochado-Kith, Oscar
  • Díez, Cristina
  • Hontañón, Víctor
  • Virseda-Berdices, Ana
  • Martínez, Javier
  • Ibañez-Samaniego, Luis
  • Llop-Herrera, Elba
  • Barbas, Coral
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
Background & aims: Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and cirrhosis induce metabolic disorders. Here, we aimed to evaluate the association of plasma metabolites with Child-Turcotte-Pugh (CTP) score and hepatic decompensation in HIV/HCV-coinfected and HCV-monoinfected patients with advanced cirrhosis. Methods: A cross-sectional study was carried out in 62 HIV/HCV-coinfected and 28 HCV-monoinfected patients. Metabolomics analysis was performed by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). The statistical association analysis was performed by partial least squares discriminant analysis (PLS-DA) and generalized linear model (GLM) with binomial distribution (to analyse HIV coinfection, high alcohol intake, treatment with statins, previous HCV therapy failure and decompensation) and ordinal logistic regression (OLR) models to analyse different stages of cirrhosis (CTP score). Results: The statistical analysis identified plasma metabolites associated with HIV coinfection, high alcohol intake, CTP score and hepatic decompensation. Overall, fatty acids, bile acids, aromatic and sulphur amino acids, butyrate derivatives, oxidized phospholipids, energy-related metabolites and bacterial fermentation-related metabolites were increased in more advanced cirrhosis stages; while lysophosphatidylcholines and lysophosphatidylethanolamines, branched-chain amino acids (BCAA) and metabolites of tricarboxylic acid cycle, among others, were decreased in more advanced cirrhosis. Most of the significant metabolites displayed a similar trend after stratifying for HIV/HCV- and HCV-infected patients. Glycolic acid, LPC (16:0) and taurocholic acid had high accuracy for discriminating patients according to decompensated cirrhosis (CTP ≥ 7). Conclusion: Altered plasma metabolomic profile was associated with advanced stages of cirrhosis in HIV/HCV-coinfected and HCV-monoinfected patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study

  • Sepulveda-Crespo, Daniel
  • Volpi, Camilla
  • Amigot-Sánchez, Rafael
  • Yélamos, María Belén
  • Díez, Cristina
  • Gómez, Julián
  • Hontañón, Víctor
  • Berenguer, Juan
  • González-García, Juan
  • Martín-Escolano, Rubén
  • Resino, Salvador
  • Martinez, Isidoro
Background: This study evaluated titers and amplitudes of anti-E2 antibodies (anti-E2-Abs) and neutralizing antibodies against hepatitis C virus (HCV; anti-HCV-nAbs) in HIV/HCV-coinfected individuals over five years after successful HCV treatment completion. Methods: We retrospectively analyzed 76 HIV/HCV-coinfected patients achieving sustained virologic response post-HCV treatment. Plasma levels of anti-E2-Abs and anti-HCV-nAbs against five HCV genotypes (Gt1a, Gt1b, Gt2a, Gt3a, and Gt4a) were determined using ELISA and microneutralization assays, respectively. Statistical analyses comparing the three follow-up time points (baseline, one year, and five years post-HCV treatment) were performed using generalized linear mixed models, adjusting p-values with the false discovery rate (q-value). Results: Compared to baseline, anti-E2-Abs titers decreased at one year (1.9- to 2.3-fold, q-value < 0.001) and five years (3.4- to 9.1-fold, q-value < 0.001) post-HCV treatment. Anti-HCV-nAbs decreased 2.9- to 8.4-fold (q-value < 0.002) at one year and 17.8- to 90.4-fold (q-value < 0.001) at five years post-HCV treatment. Anti-HCV-nAbs titers against Gt3a were consistently the lowest. Nonresponse rates for anti-E2-Abs remained low throughout the follow-up, while anti-HCV-nAbs nonresponse rates increased 1.8- to 13.5-fold (q-value < 0.05) at five years post-HCV treatment, with Gt3a showing the highest nonresponse rate. Conclusions: Humoral immune responses against HCV decreased consistently one and five years post-HCV treatment, regardless of HCV genotype and previous HCV therapy or type of treatment (IFN- or DAA-based therapy). This decline was more pronounced for anti-HCV-nAbs, particularly against Gt3.
Repisalud
Publicación Artículo científico (JournalArticle)

Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis

  • Brochado-Kith, Oscar
  • Rava, Marta
  • Berenguer, Juan
  • González-García, Juan
  • Rojo, David
  • Díez, Cristina
  • Hontañón, Víctor
  • Virseda-Berdices, Ana
  • Ibañez-Samaniego, Luis
  • Llop-Herrera, Elba
  • Olveira, Antonio
  • Pérez-Latorre, Leire
  • Barbas, Coral
  • Fernandez-Rodriguez, Amanda
  • Resino, Salvador
  • Jimenez-Sousa, Maria Angeles
  • ESCORIAL Study Group
Background: Altered bacterial translocation is associated with changes in hepatic function and the progression from compensated to decompensated cirrhosis. Child-Turcotte-Pugh (CTP) score is an essential indicator of liver severity. Thus, we aimed to study differences in the blood microbiome together with metabolome profile between HCV-infected patients with CTP class B (CTP-B, significant functional compromise) and patients with CTP class A (CTP-A, well-compensated cirrhosis). Methods: We conducted a cross-sectional study in patients with advanced HCV-related cirrhosis (n = 88) stratified by CTP-B and CTP-A. Bacterial 16S rRNA sequencing was sequenced by MiSeq Illumina technology and non-targeted metabolomics was performed by GC-MS and LC-MS ESI+ and ESI- to complement the analysis. Results: Patients with CTP-B had lower levels of richness (Chao1), and alpha diversity (Shannon and Simpson indexes) at phylum level than patients with CTP-A. Likewise, we observed significant differences in beta diversity between groups at phylum, class, and order levels, showing lower diversity in patients with CTP-B. Higher relative abundance of Proteobacteria (p = 0.012), Alphaproteobacteria (p = 0.005), Sphingomonadales (p = 0.012) and Sphingomonadaceae (p = 0.016) were significantly associated with CTP-B. The phylum Proteobacteria was positively correlated with ethanolamine and oleic acid (p = 0.005 and p = 0.004, respectively) and negatively with p-cresol (p = 0.006). In addition, the order Sphingomonadales and the family Sphingomonadaceae was also negatively correlated with p-cresol (p = 0.001 and p = 0.001). Conclusions: Blood microbial diversity was significantly decreased in patients with CTP-B, who presented an enrichment of Proteobacteria, Alphaproteobacteria, Sphingomonadales and Sphingomonadaceae compared to patients with CTP-A.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Highest dominant frequency and rotor positions are robust markers of driver location during noninvasive mapping of atrial fibrillation: A computational study

  • RODRIGO BORT, MIGUEL
  • Liberos Mascarell, Alejandro
  • Fernandez-Aviles, Francisco
  • Berenfeld, Omer
  • Atienza, Felipe
  • Andreu M. Climent|||0000-0002-7260-8811
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] BACKGROUND Dominant frequency (DF) and rotor mapping have been proposed as noninvasive techniques to guide localization of drivers maintaining atrial fibrillation (AF). OBJECTIVE The purpose of this study was to evaluate the robustness of both techniques in identifying atrial drivers noninvasively under the effect of electrical noise or model uncertainties. METHODS Inverse-computed DFs and phase maps were obtained from 30 different mathematical AF simulations. Epicardial highest dominant frequency (HDF) regions and rotor location were compared with the same inverse-computed measurements after addition of noise to the ECG, size variations of the atria, and linear or angular deviations in the atrial location inside the thorax. RESULTS Inverse-computed electrograms (EGMs) individually correlated poorly with the original EGMs in the absence of induced uncertainties (0.45 +/- 0.12) and were worse with 10-dB noise (0.22 +/- 0.11), 3-cm displacement (0.01 +/- 0.02), or 36 degrees rotation (0.02 +/- 0.03). However, inverse-computed HDF regions showed robustness against induced uncertainties: from 82% +/- 18% match for the best conditions, down to 73% +/- 23% for 10-dB noise, 77% +/- 21% for 5-cm displacement, and 60% +/- 22% for 36 degrees rotation. The distance from the inverse-computed rotor to the original rotor was also affected by uncertainties: 0.8 +/- 1.61 cm for the best conditions, 2.4 +/- 3.6 cm for 10-dB noise, 4.3 +/- 3.2 cm for 4-cm displacement, and 4.0 +/- 2.1 cm for 36 degrees rotation. Restriction of rotor detections to the HDF area increased rotor detection accuracy from 4.5 +/- 4.5 cm to 3.2 +/- 3.1 cm (P < .05) with 0-dB noise. CONCLUSION The combination of frequency and phase-derived measurements increases the accuracy of noninvasive localization of atrial rotors driving AF in the presence of noise and uncertainties in atrial location or size., This work was supported in part by grants from Generalitat Valenciana (ACIF/2013/021); Instituto de Salud Carlos III-FEDER (Fondo Europeo de Desarrollo Regional) and Ministerio de Ciencia e Innovacion (PI13-01882, PI13-00903, PI14/00857, PI16/01123, IJCI-2014-22178, DTS16/00160 and Red RIC RD12.0042.0001); Spanish Society of Cardiology (Clinical Research Grant 2015); and the National Heart, Lung, and Blood Institute (P01-HL039707, P01-HL087226, and Q1 R01-HL118304). Dr. Atienza served on the advisory board of Medtronic and Sorin. Dr. Berenfeld received research support from Medtronic and St. Jude Medical; and is a cofounder and Scientific Officer of Rhythm Solutions, Inc., Research and Development Director for S.A.S. Volta Medical, and consultant to Acutus Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Balance between sodium and calcium currents underlying chronic atrial fibrillation termination: An in silico intersubject variability study

  • Liberos Mascarell, Alejandro
  • Bueno-Orovio, Alfonso
  • Rodrigo Bort, Miguel
  • Ravens, Ursula
  • Hernández-Romero, Ismael
  • Fernández-Avilés, Francisco
  • Rodríguez López, Blanca
  • Climent, Andreu M.
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
BACKGROUND Atrial remodeling as a result of long-standing persistent atrial fibrillation (AF) induces substrate modifications that lead to different perpetuation mechanisms than in paroxysmal AF and a reduction in the efficacy of antiarrhythmic treatments. OBJECTIVE The purpose of this study was to identify the ionic current modifications that could destabilize reentries during chronic AF and serve to personalize antiarrhythmic strategies. METHODS A population of 173 mathematical models of remodeled human atrial tissue with realistic intersubject variability was developed based on action potential recordings of 149 patients diagnosed with AF. The relationship of each ionic current with AF maintenance and the dynamics of functional reentries (rotor meandering, dominant frequency) were evaluated by means of 3-dimensional simulations. RESULTS Self-sustained reentries were maintained in 126 (73%) of the simulations. AF perpetuation was associated with higher expressions of I-Na and I-caL (P < .01), with no significant differences in the remaining currents. I-caL blockade promoted AF extinction in 30% of these 126 models. The mechanism of AF termination was related with collisions between rotors because of an increase in rotor meandering (1.71 +/- 2.01cm(2)) and presented an increased efficacy in models with a depressed INa (P < .01). CONCLUSION Mathematical simulations based on a population of models representing intersubject variability allow the identification of ionic mechanisms underlying rotor dynamics and the definition of new personalized pharmacologic strategies. Our results suggest that the underlying mechanism of the diverging success of I-caL block as an antiarrhythmic strategy is dependent on the basal availability of sodium and calcium ion channel conductivities., Supported by the Spanish Ministry of Education (FPU2010); the Wellcome Trust Fellowship 100246/Z/12/Z; Universitat Politecnica de Valencia; the Spanish Health Research Fund (PI13/00903); the Spanish Society of Cardiology; the Spanish Ministry of Science; Generalitat Valenciana Grants (ACIF/2013/021); and Innovation (Red RIC, PLE2009-0152). Drs. Rodriguez and Climent are equally contributing senior authors.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Presence and stability of rotors in atrial fibrillation: evidence and therapeutic implications

  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
  • Climent, Andreu M.
  • Rodrigo Bort, Miguel
  • Fernandez-Aviles, Francisco
  • Atienza, Felipe
  • Berenfeld, Omer
[EN] Rotor-guided ablation has opened new perspectives into the therapy of atrial fibrillation (AF). Analysis of the spatio-temporal cardiac excitation patterns in the frequency and phase domains has demonstrated the importance of rotors in research models of AF, however, the dynamics and role of rotors in human AF are still controversial. In this review, the current knowledge gained through research models and patient data that support the notion that rotors are key players in AF maintenance is summarized. We report and discuss discrepancies regarding rotor prevalence and stability in various studies, which can be attributed in part to methodological differences among mapping systems. Future research for validation and improvement of current clinical electrophysiology mapping technologies will be crucial for developing mechanistic-based selection and application of the best therapeutic strategy for individual AF patient, being it, pharmaceutical, ablative, or other approach., This work was supported in part by grants from the Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain: PI13-01882, PI13-00903, and PI14/00857), Spanish Society of Cardiology (Clinical Research Grant 2015), Generalitat Valenciana (ACIF/2013/021), Innovation (Red RIC, PLE2009-0152), and NHLBI (P01-HL039707, P01-HL087226, and R01-HL118304).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Technical Considerations on Phase Mapping for Identification of Atrial Reentrant Activity in Direct- and Inverse-Computed Electrograms

  • RODRIGO BORT, MIGUEL
  • Liberos Mascarell, Alejandro
  • Fernández-Avilés, Francisco
  • Berenfeld, Omer
  • Atienza, Felipe
  • Andreu M. Climent|||0000-0002-7260-8811
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] [Background] Phase mapping has become a broadly used technique to identify atrial reentrant circuits for ablative therapy guidance. This work studies the phase mapping process and how the signal nature and its filtering affect the reentrant pattern characterization in electrogram (EGM), body surface potential mapping, and electrocardiographic imaging signals. [Methods and Results] EGM, body surface potential mapping, and electrocardiographic imaging phase maps were obtained from 17 simulations of atrial fibrillation, atrial flutter, and focal atrial tachycardia. Reentrant activity was identified by singularity point recognition in raw signals and in signals after narrow band-pass filtering at the highest dominant frequency (HDF). Reentrant activity was dominantly present in the EGM recordings only for atrial fibrillation and some atrial flutter propagations patterns, and HDF filtering allowed increasing the reentrant activity detection from 60% to 70% of time in atrial fibrillation in unipolar recordings and from 0% to 62% in bipolar. In body surface potential mapping maps, HDF filtering increased from 10% to 90% the sensitivity, although provoked a residual false reentrant activity ¿30% of time. In electrocardiographic imaging, HDF filtering allowed to increase ¿100% the time with detected rotors, although provoked the apparition of false rotors during 100% of time. Nevertheless, raw electrocardiographic imaging phase maps presented reentrant activity just in atrial fibrillation recordings accounting for ¿80% of time. [Conclusions] Rotor identification is accurate and sensitive and does not require additional signal processing in measured or noninvasively computed unipolar EGMs. Bipolar EGMs and body surface potential mapping do require HDF filtering to detect rotors at the expense of a decreased specificity., This study was supported, in part, by Universitat Politecnica de Valencia through its research initiative program; Generalitat Valenciana Grants (ACIF/2013/021); the Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain: PI13-01882, PI13-00903, PI14/00857, PI16/01123, TEC2013-46067-R, DTS16/0160, and IJCI-2014-22178); Spanish Society of Cardiology (Grant for Clinical Research in Cardiology 2015); Spanish Ministry of Science and Innovation (Red RIC RD12.0042.0001); and the National Heart, Lung, and Blood Institute (P01-HL039707, P01-HL087226, and Q1 R01-HL118304) and cofounded by FEDER.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Standardizing Single-Frame Phase Singularity Identification Algorithms and Parameters in Phase Mapping During Human Atrial Fibrillation

  • Li, Xin
  • Almeida, Tiago P.
  • Dastagir, Nawshin
  • Salinet, Joao
  • Chu, Gavin S.
  • Stafford, Peter J.
  • Schlindwein, Fernando S.
  • Ng, G. André
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] Purpose Recent investigations failed to reproduce the positive rotor-guided ablation outcomes shown by initial studies for treating persistent atrial fibrillation (persAF). Phase singularity (PS) is an important feature for AF driver detection, but algorithms for automated PS identification differ. We aim to investigate the performance of four different techniques for automated PS detection. Methods 2048-channel virtual electrogram (VEGM) and electrocardiogram signals were collected for 30 s from 10 patients undergoing persAF ablation. QRST-subtraction was performed and VEGMs were processed using sinusoidal wavelet reconstruction. The phase was obtained using Hilbert transform. PSs were detected using four algorithms: (1) 2D image processing based and neighbor-indexing algorithm; (2) 3D neighbor-indexing algorithm; (3) 2D kernel convolutional algorithm estimating topological charge; (4) topological charge estimation on 3D mesh. PS annotations were compared using the structural similarity index (SSIM) and Pearson's correlation coefficient (CORR). Optimized parameters to improve detection accuracy were found for all four algorithms usingF(beta)score and 10-fold cross-validation compared with manual annotation. Local clustering with density-based spatial clustering of applications with noise (DBSCAN) was proposed to improve algorithms 3 and 4. Results The PS density maps created by each algorithm with default parameters were poorly correlated. Phase gradient threshold and search radius (or kernels) were shown to affect PS detections. The processing times for the algorithms were significantly different (p< 0.0001). TheF(beta)scores for algorithms 1, 2, 3, 3 + DBSCAN, 4 and 4 + DBSCAN were 0.547, 0.645, 0.742, 0.828, 0.656, and 0.831. Algorithm 4 + DBSCAN achieved the best classification performance with acceptable processing time (2.0 +/- 0.3 s). Conclusion AF driver identification is dependent on the PS detection algorithms and their parameters, which could explain some of the inconsistencies in rotor-guided ablation outcomes in different studies. For 3D triangulated meshes, algorithm 4 + DBSCAN with optimal parameters was the best solution for real-time, automated PS detection due to accuracy and speed. Similarly, algorithm 3 + DBSCAN with optimal parameters is preferred for uniform 2D meshes. Such algorithms - and parameters - should be preferred in future clinical studies for identifying AF drivers and minimizing methodological heterogeneities. This would facilitate comparisons in rotor-guided ablation outcomes in future works., This work was supported by the NIHR Leicester Biomedical Research Centre, UK. XL received research grants from Medical Research Council UK (MRC DPFS Ref: MR/S037306/1). TA received research grants from the British Heart Foundation (BHF Project Grant No. PG/18/33/33780), BHF Research Accelerator Award funding and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil, Grant No. 2017/00319-8). MG research was funded by a research grant from the Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain: PI13-00903). GN received funding from the British Heart Foundation (BHF Programme Grant, RG/17/3/32774).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Electrophysiological characteristics of permanent atrial fibrillation: insights from research models of cardiac remodeling

  • Climent, A.M.
  • Atienza Fernández, Felipe
  • Fernandez-Aviles, F.
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] Atrial fibrillation (AF) results in a remodeling of the electrical and structural characteristics of the cardiac tissue which dramatically reduces the efficacy of pharmacological and catheter-based ablation therapies. Recent experimental and clinical results have demonstrated that the complexity of the fibrillatory process significantly differs in paroxysmal versus persistent AF; however, the lack of appropriate research models of remodeled atrial tissue precludes the elucidation of the underlying AF mechanisms and the identification of appropriated therapeutic targets. Here, we summarize the different research models used to date, highlighting the lessons learned from them and pointing to the new doors that should be open for the development of innovative treatments for AF., The authors were supported by grants from the Spanish Ministry of Science and Innovation (PLE2009-0152), the Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain: PI13-01882 and PI13-00903) the Red de Investigacion Cardiovacular (RIC) from Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain). F Atienza served on the advisory board of Medtronic and has received research funding from St. Jude Medical Spain. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Spatiotemporal Characteristics of QRS Complexes Enable the Diagnosis of Brugada Syndrome Regardless of the Appearance of a Type 1 ECG

  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
  • Millet Roig, José|||0000-0002-8879-003X
  • M. Climent, Andreu
  • Berne, P
  • Ramos, R
  • Brugada, J
  • Brugada, R
[EN] Abstract INTRODUCTION: The diagnosis of Brugada syndrome based on the ECG is hampered by the dynamic nature of its ECG manifestations. Brugada syndrome patients are only 25% likely to present a type 1 ECG. The objective of this study is to provide an ECG diagnostic criterion for Brugada syndrome patients that can be applied consistently even in the absence of a type 1 ECG. METHODS AND RESULTS: We recorded 67-lead body surface potential maps from 94 Brugada syndrome patients and 82 controls (including right bundle branch block patients and healthy individuals). The spatial propagation direction during the last r' wave and the slope at the end of the QRS complex were measured and compared between patients groups. Receiver-operating characteristic curves were constructed for half of the database to identify optimal cutoff values; sensitivity and specificity for these cutoff values were measured in the other half of the database. A spontaneous type 1 ECG was present in only 30% of BrS patients. An orientation in the sagittal plane < 101º during the last r' wave and a descending slope < 9.65 mV/s enables the diagnosis of the syndrome with a sensitivity of 69% and a specificity of 97% in non-type 1 Brugada syndrome patients. CONCLUSION: Spatiotemporal characteristics of surface ECG recordings can enable a robust identification of BrS even without the presence of a type 1 ECG., Supported in part by: Universitat Politecnica de València through its research initiative program (PAID-2009-2013); Generalitat Valenciana Grants (ACIF/2013/021); the Instituto de Salud Carlos III (Ministry of Economy and Competitiveness, Spain: PI13-01882, PI13-00903); Spanish Ministry Science and Innovation (TEC2009-13939).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Solving Inaccuracies in Anatomical Models for Electrocardiographic Inverse Problem Resolution by Maximizing Reconstruction Quality

  • Rodrigo Bort, Miguel
  • Liberos Mascarell, Alejandro
  • Hernández-Romero, Ismael
  • Arenal, A.
  • Bermejo, Javier
  • Fernández-Avilés, Francisco
  • Atienza, Felipe
  • Andreu M. Climent|||0000-0002-7260-8811
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] Electrocardiographic Imaging has become an increasingly used technique for non-invasive diagnosis of cardiac arrhythmias, although the need for medical imaging technology to determine the anatomy hinders its introduction in the clinical practice. This paper explores the ability of a new metric based on the inverse reconstruction quality for the location and orientation of the atrial surface inside the torso. Body surface electrical signals from 31 realistic mathematical models and four AF patients were used to estimate the optimal position of the atria inside the torso. The curvature of the L-curve from the Tikhonov method, which was found to be related to the inverse reconstruction quality, was measured after application of deviations in atrial position and orientation. Independent deviations in the atrial position were solved by finding the maximal L-curve curvature with an error of 1.7 +/- 2.4 mm in mathematical models and 9.1 +/- 11.5 mm in patients. For the case of independent angular deviations, the error in location by using the L-curve was 5.8 +/- 7.1 degrees in mathematical models and 12.4 degrees +/- 13.2 degrees in patients. The ability of the L-curve curvature was tested also under superimposed uncertainties in the three axis of translation and in the three axis of rotation, and the error in location was of 2.3 +/- 3.2 mm and 6.4 degrees +/- 7.1 degrees in mathematical models, and 7.9 +/- 10.7 mm and 12.1 degrees +/- 15.5 degrees in patients. The curvature of L-curve is a useful marker for the atrial position and would allow emending the inaccuracies in its location., This work was supported in part by Generalitat Valenciana under Grant ACIF/2013/021, in part by the Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain, under Grant PI13-01882, Grant PI13-00903, Grant PI14/00857, Grant TEC2013-46067-R, and Grant DTS16/00160, in part by the Spanish Society of Cardiology (Grant for Clinical Research in Cardiology 2015), and in part by the Spanish Ministry of Science and Innovation (Red RIC) under Grant PLE2009-0152.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Interplay between the oxidation process and cytotoxic effects of antimonene nanomaterials

  • Congost-Escoin, Pau
  • Lucherelli, Matteo Andrea
  • Oestreicher, Víctor
  • García-Lainez, Guillermo
  • Alcaraz, Marta
  • Mizrahi, Martin
  • Varela, Maria
  • Abellán, Gonzalo
  • Andreu, Inmaculada|||0000-0003-3409-9443
[EN] Pnictogen nanomaterials have recently attracted researchers' attention owing to their promising properties in the field of electronic, energy storage, and nanomedicine applications. Moreover, especially in the case of heavy pnictogens, their chemistry allows for nanomaterial synthesis using both top-down and bottom-up approaches, yielding materials with remarkable differences in terms of morphology, size, yield, and properties. In this study, we carried out a comprehensive structural and spectroscopic characterization of antimony-based nanomaterials (Sb-nanomaterials) obtained by applying different production methodologies (bottom-up and top-down routes) and investigating the influence of the synthesis on their oxidation state and stability in a biological environment. Indeed, in situ XANES/EXAFS studies of Sb-nanomaterials incubated in cell culture media were carried out, unveiling a different oxidation behavior. Furthermore, we investigated the cytotoxic effects of Sb-nanomaterials on six different cell lines: two non-cancerous (FSK and HEK293) and four cancerous (HeLa, SKBR3, THP-1, and A549). The results reveal that hexagonal antimonene (Sb-H) synthesized using a colloidal approach oxidizes the most and faster in cell culture media compared to liquid phase exfoliated (LPE) antimonene, suffering acute degradation and anticipating well-differentiated toxicity from its peers. In addition, the study highlights the importance of the synthetic route for the Sb-nanomaterials as it was observed to influence the chemical evolution of Sb-H into toxic Sb oxide species, playing a critical role in its ability to rapidly eliminate tumor cells. These findings provide insights into the mechanisms underlying the dark cytotoxicity of Sb-H and other related Sb-nanomaterials, underlining the importance of developing therapies based on controlled and on-demand nanomaterial oxidation.; Study of three antimony-based nanomaterials' behaviour in biological conditions and the influence of the synthesis on their oxidation state and stability in this environment., This work has been supported by the Universitat de Valencia and Instituto de Investigacion Sanitaria del Hospital La Fe de Valencia (VLC-BIOMED AP2022-27), the European Union (ERC-2018-StG 804110-2D-PnictoChem to G.A.), the Spanish MICINN (PID2022-143297NB-I00, PDC2022-133997-I00, TED2021-131347B-I00, PID2021-122980OB-C51, TED and Excellence Unit Maria de Maeztu CEX2019-000919-M), the Generalitat Valenciana (CIDEGENT/2018/001) and Comunidad de Madrid "Materiales Avanzados MAD2D-CM (UCM3)". We also want to acknowledge ALBA Synchrotron for their collaboration in the project 2021095421 performed at BL22-CLAESS beamline. P. C.-E. acknowledges the PhD grant PRE2021-100943 funded by MICIU/AEI/10.13039/501100011033 and by "ESF+". M. A. L. acknowledges the Generalitat Valenciana for a postdoctoral fellowship (CIAPOS/2021/255). M. M. is a research member from CONICET (Argentina) and thanks to the financial support of the institution, from the Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT, PICT 2021-I-A-00903), and from Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP, X-937).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Identification of Dominant Excitation Patterns and Sources of Atrial Fibrillation by Causality Analysis

  • Rodrigo Bort, Miguel
  • Climent, A.M.
  • Liberos Mascarell, Alejandro
  • Calvo, D.
  • Fernandez-Aviles, F.
  • Berenfeld, O.
  • Atienza, F.
  • Guillem, M.S
Burden of atrial fibrillation (AF) can be reduced by ablation of sources of electrical impulses driving AF but driver identification is still challenging. This study presents a new methodology based on causality analysis that allows identifying the hierarchically dominant areas driving AF. Identification of dominant propagation patterns was achieved by computing causal relations between intracardiac multi-electrode catheter recordings of four paroxysmal AF patients during sinus rhythm, pacing and AF. In addition, realistic mathematical models of the atria during AF were used to validate the methodology both in the presence and absence of dominant frequency (DF) gradients. During electrical pacing, sources of propagation patterns detected by causality analysis were consistent with the location of the stimulating catheter. During AF, propagation patterns presented temporal variability, but a dominant direction accounted for significantly more propagations than other directions (49 +/- 15% vs. 14 +/- 13% or less, p < 0.01). Both in patients with a DF gradient and in mathematical models, causal maps allowed the identification of sites responsible for maintenance of AF. Causal maps allowed the identification of atrial dominant sites. In particular, causality analysis resulted in stable dominant cause-effect propagation directions during AF and could serve as a guide for performing ablation procedures in AF patients., FA served on the advisory board of Medtronic and has received research funding from St. Jude Medical Spain. OB received research support from Medtronic and St. Jude Medical. He is a Scientific Officer of Rhythm Solutions, Inc. and a consultant to Acutus Medical, inc. The other authors have no conflict of interest. None of the companies disclosed financed the research described in this manuscript.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Minimal configuration of body surface potential mapping for discrimination of left versus right dominant frequencies during atrial fibrillation

  • RODRIGO BORT, MIGUEL
  • Liberos Mascarell, Alejandro
  • Fernández-Avilés, Francisco
  • Atienza, Felipe
  • Berenfeld, Omer
  • Andreu M. Climent|||0000-0002-7260-8811
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] Background: Ablation of drivers maintaining atrial fibrillation (AF) has been demonstrated as an effective therapy. Drivers in the form of rapidly activated atrial regions can be noninvasively localized to either left or right atria (LA, RA) with body surface potential mapping (BSPM) systems. This study quantifies the accuracy of dominant frequency (DF) measurements from reduced-leads BSPM systems and assesses the minimal configuration required for ablation guidance. Methods: Nine uniformly distributed lead sets of eight to 66 electrodes were evaluated. BSPM signals were registered simultaneously with intracardiac electrocardiograms (EGMs) in 16 AF patients. DF activity was analyzed on the surface potentials for the nine leads configurations, and the noninvasive measures were compared with the EGM recordings. Results: Surface DF measurements presented similar values than panoramic invasive EGM recordings, showing the highest DF regions in corresponding locations. The noninvasive DFs measures had a high correlation with the invasive discrete recordings; they presented a deviation of <0.5 Hz for the highest DF and a correlation coefficient of >0.8 for leads configurations with 12 or more electrodes. Conclusions: Reduced-leads BSPM systems enable noninvasive discrimination between LA versus RA DFs with similar results as higher-resolution 66-leads system. Our findings demonstrate the possible incorporation of simplified BSPM systems into clinical planning procedures for AF ablation., This work was supported in part by Generalitat-Valenciana Grants [ACIF/2013/021]; Instituto de SaludCarlos III, Ministerio de Ciencia e Innovacion [PI13/00903, PI13-01882, PI14/00857, PI16/01123, TEC2013-46067-R, DTS16/0160 and IJCI-2014-22178] cofound by FEDER.; Spanish Society of Cardiology [Clinical research Grants 2015]; Ministerio de Ciencia e Innovacion [Red RICRD12.0042.0001]; and the National Heart, Lung, and Blood Institute [P01-HL039707, P01-HL087226 and R01-HL118304].
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

La delimitación del ius puniendi del Estado atribuido a sujetos privados: el caso de las entidades deportivas en la ley española del deporte, The Delimitation of the Ius Puniendi of the State Attributed to Private Subjetcs: The Case of Sports Entities in Spanish Sports Act

  • León Acosta, Miguel
El trabajo tiene como objeto delimitar el ius puniendi de las entidades depor­tivas en España después de la aprobación de la Ley 39/2022, del 30 de diciembre, Ley del Deporte. Asimismo, como cuestión previa y necesaria, se aborda la discutida la naturaleza jurídica de las federaciones españolas y ligas profesionales. Al respecto, se sostiene en el escrito que las federaciones españolas y ligas profesionales tienen naturaleza privada y que la distinción que se hace en la Ley 39/2022 entre funciones públicas y privadas de las federaciones españolas aparece equívoca, exponiendo cuál es el criterio de delimitación entre su ius puniendi privado y el del Estado., This paper analyses the delimitation between the ius puniendi of sports entities in Spain following the enactement of the new Act 39/2022, dated December 30, on Sports. As a preliminary matter, it discusses the legal nature of Spanish federations and professional leagues. It maintains that Spanish federations and professional leagues are inherently private entities, and argues that the distinction made in Law 39/2022 between the public and private functions of Spanish federations seems misleading. Furthermore, it explains the criteria for distinguishing between their private ius puniendi and that of the State.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

El ejercicio del ius puniendi por sujetos privados. A propósito del artículo 107.4 de la Ley 6/2011 de Movilidad de la Comunidad Valenciana, The exercise of ius puniendi by private persons. Regarding article 107.4 of Law 6/2011 on Mobility of the Valencian Community

  • León Acosta, Miguel
Embargado hasta 01/01/2100, El objeto del presente trabajo es reflexionar sobre una parcela de una cuestión clásica del Derecho: el ejercicio del ius puniendi por sujetos privados, utilizando como caso testigo el sector del transporte público terrestre de viajeros, en particular, en la Comunidad Valenciana. En concreto, han sido tres las cuestiones abordadas. En primer lugar, si la Administración pública puede confiar su poder sancionador a un sujeto privado. En segundo lugar, en caso contrario, si puede hacerlo el Legislador, bien directamente o bien habilitando a la Administración para ello. Y, por último, se ha estudiado a qué principios y normas estaría sujeto, en su caso, el privado que ejerceriera el ius puniendi; haciendo en este punto especial hincapié entre la distinción del Derecho público y el Derecho privado y las consecuencias de la aplicación de uno u otro., The purpose of this paper is to reflect on a classic legal issue: the exercise of ius puniendi by private persons, using the public passenger transport sector as a case study, particularly in the Valencian Community. Specifically, three questions have been addressed. Firstly, we wonder whether the public administration can entrust its sanctioning power to a private party. Secondly, if not, whether the Legislator can do so, either directly or by empowering the Administration to do so. And finally, what principles and rules must be applied when a private person is exercising ius puniendi. Regarding to this, we study with special emphasis the distinction between public law and private law and the consequences of the application of one or the other.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia
  • González-García, Juan
  • Jiménez-Sousa, María Ángeles
  • Guardiola, Josep M.
  • GESIDA 3603b Cohort Study Group
  • Berenguer, Juan
Sustained virological response (SVR); Anti-HCV therapy; HIV/HCV-coinfected patients, Respuesta virológica sostenida (RVS); Terapia anti-VHC; Pacientes coinfectados por VIH/VHC, Resposta virològica sostinguda (RVS); Teràpia anti-VHC; Pacients infectats amb VIH/VHC, The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR., The HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by the Institute of Health Carlos III, ISCIII, Spanish Health Ministry (Grant nº RD06/0006/0035 and RD12/0017/0037) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF) and Foundation for Research and Prevention of AIDS in Spain (FIPSE). The RIS Cohort (CoRIS) is funded by the ISCIII through the Spanish AIDS Research Network (RIS C03/173 and RD12/0017/0018) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF). This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI14/01094 and PI17/00657 to JB, PI17/00903 to JGG, PI14CIII/00011 and PI17CIII/00003 to SR) and Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11-241). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0018, and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration, Randomized crossover clinical trial in healthy volunteers

  • Barroso, Sergio|||0000-0001-7504-4794
  • Morén, Constanza|||0000-0001-6848-7407
  • González-Segura, Àlex|||0000-0002-9398-2183
  • Riba, Neus
  • Arnaiz, Joan Albert
  • Manríquez, Marcela
  • Santana, Gemina
  • Blanco Arévalo, José Luis|||0000-0003-2010-2744
  • Larousse, María
  • Loncà, Montse
  • de Lazzari, Elisa|||0000-0003-2614-6545
  • Llopis, Jaume
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Miró, Oscar|||0000-0002-7924-9751
  • Carné, Xavier
  • Gatell, José Mª|||0000-0002-4705-3244
  • Garrabou, Glòria|||0000-0001-8973-9933
  • Martínez, Esteban|||0000-0002-6911-8846
Context Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and integrase inhibitors are supposed to be safer, but have been scarcely investigated. To avoid any interference with HIV or other antiretrovirals, we assessed markers of these toxicities in healthy adult volunteers treated with Enfuvirtide (T20) or Raltegravir (RAL). Methods Twenty-six healthy participants were randomized to T20/90mg vs. placebo (n = 12) or RAL/ 400mg vs. placebo (n = 14) every 12h in two 7-day periods separated by a 4-week washout period. Major end-points were changes in lipid profile (total cholesterol, high-density-lipoprotein (HDL)-cholesterol, low-density-lipoprotein (LDL)-cholesterol, triglycerides), insulin resistance (glucose) and mitochondrial toxicity (mitochondrial DNA content-mtDNA-in peripheral blood mononuclear cells). Renal and hepatic toxicity (creatinine, alanine transaminase (AST), alanine aminotransferase (ALT), bilirubin and total plasma proteins) and overall safety were also analysed. Effect of period, treatment, and basal measures were evaluated for each end-point. Results Neither T20-administration nor RAL-administration yielded to any statistic significant change in the markers of metabolic, mitochondrial, renal or hepatic toxicity assessed. No symptoms indicative of drug toxicity were neither found in any subject. Conclusions In absence of HIV infection, or concomitant treatment, short-term exposure to T20 or RAL in healthy adult volunteers did not lead to any indicative changes in toxicity markers thus presuming the safe profile of both drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex Differences and the Influence of an Active Lifestyle on Adiposity in Patients with McArdle Disease

  • Rodríguez-Gómez, Irene|||0000-0002-1622-7109
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Díez Bermejo, Jorge
  • Munguía-Izquierdo, Diego|||0000-0001-7817-747X
  • Alegre, Luis M.|||0000-0002-4502-9275
  • Nogales, Gisela|||0000-0002-7414-212X
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Ara, Ignacio|||0000-0002-2854-6684
McArdle disease (glycogenosis-V) is associated with exercise intolerance, however, how it affects an important marker of cardiometabolic health as it is adiposity remains unknown. We evaluated the association between physical activity (PA) and adiposity in patients with McArdle disease. We assessed 199 adults of both sexes (51 McArdle patients (36 ± 11 years) and 148 healthy controls (35 ± 10 years)). Body fat (BF) was determined using dual-energy X-ray absorptiometry (DXA) method and each patient's PA was assessed with the International PA Questionnaire (IPAQ). Although body mass index values did not differ between patients and controls, McArdle patients had significantly higher values of BF in all body regions (p < 0.05) and higher risk of suffering obesity (odds ratio (OR): 2.54, 95% confidence interval (95% CI): 1.32-4.88). Male patients had higher BF and obesity risk (OR: 3.69, 95% CI: 1.46-9.34) than their sex-matched controls, but no differences were found within the female sex (p < 0.05). In turn, active female patients had lower trunk BF than their inactive peers (p < 0.05). Males with McArdle seem to have adiposity problems and a higher risk of developing obesity than people without the condition, while female patients show similar or even better levels in the trunk region with an active lifestyle. Therefore, special attention should be given to decrease adiposity and reduce obesity risk in males with McArdle disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genotypic and phenotypic features of all Spanish patients with McArdle disease, a 2016 update

  • Santalla, Alfredo|||0000-0001-9418-0564
  • Nogales, Gisela|||0000-0002-7414-212X
  • Encinar, Alberto Blazquez
  • Vieitez, Irene
  • González-Quintana, Adrian
  • Serrano-Lorenzo, Pablo|||0000-0002-5661-7574
  • Consuegra-García, Inés
  • Asensio-Peña, Sara|||0000-0002-2048-5899
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Pareja-Galeano, Helios
  • Díez Bermejo, Jorge
  • Pérez Ruiz, Margarita|||0000-0001-7240-2082
  • Andreu Périz, Antoni Lluís
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Lucia, Alejandro|||0000-0002-3025-2060
We recently described the genotype/phenotype features of all Spanish patients diagnosed with McArdle disease as of January 2011 (n = 239, prevalence of ~1/167,000) (J Neurol Neurosurg Psychiatry 2012;83:322-8). Several caveats were however identified suggesting that the prevalence of the disease is actually higher. We have now updated main genotype/phenotype data, as well as potential associations within/between them, of all Spanish individuals currently diagnosed with McArdle disease (December 2016). Ninety-four new patients (all Caucasian) have been diagnosed, yielding a prevalence of ~1/139,543 individuals. Around 55% of the mutated alleles have the commonest PYGM pathogenic mutation p.R50X, whereas p.W798R and p.G205S account for 10 and 9% of the allelic variants, respectively. Seven new mutations were identified: p.H35R, p.R70C, p.R94Q, p.L132WfsX163, p.Q176P, p.R576Q, and c.244-3_244-2CA. Almost all patients show exercise intolerance, the second wind phenomenon and high serum creatine kinase activity. There is, however, heterogeneity in clinical severity, with 8% of patients being asymptomatic during normal daily life, and 21% showing limitations during daily activities and fixed muscle weakness. A major remaining challenge is one of diagnosis, which is often delayed until the third decade of life in 72% of new patients despite the vast majority (86%) reporting symptoms before 20 years. An important development is the growing proportion of those reporting a 4-year improvement in disease severity (now 34%) and following an active lifestyle (50%). Physically active patients are more likely to report an improvement after a 4-year period in the clinical course of the disease than their inactive peers (odds ratio: 13.98; 95% confidence interval: 5.6, 34.9; p < 0.001). Peak oxygen uptake is also higher in the former (20.7 ± 6.0 vs. 16.8 ± 5.3 mL/kg/min, p = 0.0013). Finally, there is no association between PYGM genotype and phenotype manifestation of the disease. The reported prevalence of McArdle disease grows exponentially despite frequent, long delays in genetic diagnosis, suggesting that many patients remain undiagnosed. Until a genetic cure is available (which is not predicted in the near future), current epidemiologic data support that adoption of an active lifestyle is the best medicine for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado Kith, Óscar|||0000-0001-8372-2604
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Berenguer, Juan|||0000-0001-8541-8200
  • Medrano, Luz María|||0000-0003-3717-5384
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, María Ángeles|||0000-0002-1945-6169
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Navarro, Jordi|||0000-0002-7187-0367
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Resino, Salvador|||0000-0001-8783-0450
Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results: HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion: HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia
  • González-García, Juan
  • Jiménez-Sousa, María Ángeles
  • Guardiola, Josep M.
  • GESIDA 3603b Cohort Study Group
  • Berenguer, Juan
Sustained virological response (SVR); Anti-HCV therapy; HIV/HCV-coinfected patients, Respuesta virológica sostenida (RVS); Terapia anti-VHC; Pacientes coinfectados por VIH/VHC, Resposta virològica sostinguda (RVS); Teràpia anti-VHC; Pacients infectats amb VIH/VHC, The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR., The HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by the Institute of Health Carlos III, ISCIII, Spanish Health Ministry (Grant nº RD06/0006/0035 and RD12/0017/0037) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF) and Foundation for Research and Prevention of AIDS in Spain (FIPSE). The RIS Cohort (CoRIS) is funded by the ISCIII through the Spanish AIDS Research Network (RIS C03/173 and RD12/0017/0018) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF). This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI14/01094 and PI17/00657 to JB, PI17/00903 to JGG, PI14CIII/00011 and PI17CIII/00003 to SR) and Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11-241). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0018, and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100.